VION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition

Show all filings for VION PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for VION PHARMACEUTICALS INC 16-Nov-2009Results of Operations and Financial Condition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informationa...
Click here to read the whole Article (external link)

VION PHARMACEUTICALS INC Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

Vion Pharmaceuticals Earnings Call scheduled for 8:30 am ET today

Call DetailsVion Pharmaceuticals Earnings Conference Call (Q3 2009)Thu, Nov 12, 2009, 8:30 am EasternAbout Vion Pharmaceuticals (OTC BB:VION.OB)Vion Pharmaceuticals, Inc., a development-stage pharmaceutical company, develops and commercializes therapeutics for the treatment of cancer. It has two agents in clinical trials, Onrigin and Triapine. Onrigin, a novel alkylating agent that damages DNA to prevent cancer cells from reproducing, is in various clinical trials for the treatment of various indications, such as acute myeloid leukemia (AML), relapsed AML, de novo poor-risk, small cell lung cancer, brain tumors, myelodysplastic syndromes, chronic lymphocytic leukemia, hematologic malignancies, and solid tumors. Triapine is a small molecule in various clinical trials to prevent the replication of tumor cells by blocking a critical step in DNA synthesis. The company’s other products and product candidates include MELASYN, a water-soluble, synthetic version of melanin for formulation of skin care products and cosmetics; and Nucleoside Analogs, known as elvucitabine, which is in Phase II clinical trials as an antiviral drug for the treatment of human immunodeficiency virus. Vion Pharmaceuticals has licensing and research agreement with Yale University. The company was formerly known as OncoRx, Inc. and changed its name to Vion Pharmaceuticals, Inc. in April 1996. Vion Pharmaceuticals was founded in 1992 and is based in New Haven, Connecticut.More Info:Quote |Profile |Reports |Research |SEC |...
Click here to read the whole Article (external link)

Vion Pharmaceuticals Reports 2009 Third Quarter and Nine-Month Results

NEW HAVEN, Conn., Nov. 10 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION - News) today announced financial results for the three-month and nine-month periods ending September 30, 2009. For the third quarter of 2009, the Company reported a net loss of $6.2 million, or $0.78 per share, compared with a net loss of $6.8 million, or $0.92 per share, for the same 2008 period. Weighted-average common shares outstanding for the three-month periods ended September 30, 2009 and 2008 were 8.0 million and 7.4 million, respectively.For the nine-month period, the net loss was $17.1 million, or $2.15 per share, compared with a net loss of $22.9 million, or $3.12 per share, for the same 2008 period. Weighted-average common shares outstanding for the nine-month periods ended September 30, 2009 and 2008 were 8.0 million and 7.4 million, respectively.In the quarter, the Oncologic Drugs Advisory Committee (ODAC), which is the cancer drug advisory panel of the U.S. Food and Drug Administration (FDA), voted in favor of requiring Vion to complete a randomized study defining the efficacy and safety of the Company's lead oncology therapeutic Onrigin(TM) (laromustine) Injection prior to receiving regulatory approval from the FDA. Vion currently does not have the funds to conduct such a randomized trial.On October 12, 2009, the Company announced it had hired the investment banking firm Merriman Curhan Ford & Co. to assist in evaluating its strategic alternatives. These alternatives includ...
Click here to read the whole Article (external link)

VION PHARMACEUTICALS INC Files SEC form 8-K, Other Events

Show all filings for VION PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for VION PHARMACEUTICALS INC 13-Oct-2009Other Events Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended f...
Click here to read the whole Article (external link)

Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives

NEW HAVEN, Conn., Oct. 12 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION - News) announced today that it had hired the investment banking firm Merriman Curhan Ford & Co. to assist in evaluating its strategic alternatives. These alternatives include any combination of a restructuring of the Company and its debt and a sale of the Company or its assets. The Company may also consider financing options. de novo poor-risk acute myeloid leukemia (AML). As Vion would need to raise additional capital to finance a new randomized trial, the Company is evaluating its strategic alternatives. If Vion is unsuccessful in achieving a restructuring, sale, financing or any other strategic transaction or combination thereof, it may have to consider curtailing or ceasing operations or liquidating its assets.About Vion Pharmaceuticalsde novo poor-risk AML. The FDA's Oncologic Drug Advisory Committee has recommended to the FDA that a new randomized trial for Onrigin(TM) be completed prior to regulatory approval. Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionph...
Click here to read the whole Article (external link)

Skymark Research Initiates Independent Research Coverage On Vion Pharmaceuticals, Inc.

CALGARY, Alberta, Sept. 10, 2009 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Vion Pharmaceuticals, Inc.(OTCBB:VION - News). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com About SMR: Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to ...
Click here to read the whole Article (external link)

VION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers

Show all filings for VION PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for VION PHARMACEUTICALS INC 9-Sep-2009Change in Directors or Principal Officers Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational pur...
Click here to read the whole Article (external link)

Vion Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference

NEW HAVEN, Conn., Sept. 9 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION - News) today announced that it would make a corporate presentation at the 11th Annual Rodman & Renshaw Healthcare Conference in New York City. The presentation will be on Thursday, September 10, 2009 at 5:45 p.m. in the Hubbard Salon, 5th Floor, of the New York Palace Hotel.Slides from the presentation will be available on the Company's website, www.vionpharm.com, at the time of the presentation.About Vion Pharmaceuticalsde novo poor-risk AML. The FDA's Oncologic Drug Advisory Committee has recommended to the FDA that a new randomized trial for Onrigin be completed prior to regulatory approval. Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or re...
Click here to read the whole Article (external link)

FDA Panel Recommends Approval for Allos Cancer Drug

Stock quotes in this article: ALTH , VION.OB , GENZ , ...
Click here to read the whole Article (external link)